Bristol-Myers Squibb Co

Explore Bristol‑Myers Squibb’s strategic growth: institutional confidence, mental‑health partnership, and solid market outlook—why BMY stands out in biopharma.

Raymond James keeps Bristol‑Myers Squibb at “Market Perform,” citing steady $59 price, solid guidance, and solid valuation—stable play for pharma‑sector investors.

UBS lifts Bristol‑Myers Squibb’s target price ahead of Milvexian data, boosting investor outlook on its anticoagulant pipeline and potential growth.

Explore Bristol‑Myers Squibb’s $0.63 dividend, analyst praise, and booming biliary tract cancer market – a winning mix for investors in 2026.

Explore Bristol‑Myers Squibb’s AI partnership with Microsoft—how it may reshape cancer diagnostics, analysts’ split views, and the stock’s valuation prospects.

Explore Bristol‑Myers Squibb’s rising analyst support, $60 price target bump, and 17.3% six‑month rally—why BMY’s stock may soon hit its $63.33 high.

Explore Bristol‑Myers Squibb’s value‑chance: strong cash flow, dividend yield and a high‑growth pipeline could boost the stock beyond its current volatility.

Explore how Bristol‑Myers Squibb’s FDA approval of Breyanzi for MZL is sparking a surge in shareholder value, analyst upgrades, and a promising oncology pipeline.

Explore Bristol‑Myers Squibb’s 2025 Q3 surge, new Sotyktu safety data, and bold Metsera bid—how this biopharma giant balances growth, value, and dividend returns.

Explore how Bristol‑Myers Squibb’s Q3 earnings and new Sotyktu data reveal a resilient growth engine amid patent pressure and strategic biotech moves.